Pharmaceutical Sector Shows Promising Signs in 2025 Annual Reports, Underlying Growth Drivers Strengthened

YSB Reports 2025 Net Profit of 153 Million Yuan, Anticipates Further Growth from Own-Brand Segment

Vincentage Pharma Mulls Hong Kong IPO with $100-200 Million Fundraising Target

CLSA Raises Target Price for GENFLEET-B to HK$61.9, Keeps Outperform Rating

Long-Term Care Insurance System to Start at Municipal Level, Avoids Uniform Implementation

TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference

Truking Technology's Subsidiary Focuses on Robotics in Pharmaceutical and Adjacent Sectors

HENLIUS: Earnings Exceed Expectations, Pipeline and Performance Set for Dual Gains

GENFLEET-B Announces Appointment of Huang Meifeng as Co-Company Secretary

GENFLEET-B Reports Annual Loss Widening to 17.95 Billion Yuan

Pharmaceutical Leaders Demonstrate Sustained High Performance, Undervalued Biotech Sector Presents Attractive Opportunities

Chinese Stock Market Sees Sudden Shift: Wanbangde Hits Limit-Up Before Noon; Pharmaceutical Stocks Rally

Profitability Turning Point for Innovative Drugs Confirmed, Fullgoal Fund Targets Core Sector

Wellington Management Increases Stake in GENFLEET-B by 3.82 Million Shares at HK$25.5 Each

GENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting

Three Chinese Firms Including Tiandi Science & Technology Have IPO Applications Accepted by Regulator

Haina Pharmaceutical's Third IPO Attempt: Cash Flow Strain and Persistent Profit Decline Challenge Generic Drug CXO Narrative

Wellington Management Group LLP Increases Stake in GENFLEET-B by 2.524 Million Shares

CHINARES PHARMA (03320) Reports Tasly Pharmaceutical's 2025 Net Profit Attributable to Shareholders at RMB 1.105 Billion, Up 15.63%

Official Approval Granted: Two Vocational Colleges in Shandong Upgrade to University Status, Binzhou Medical College Renamed Shandong Medical University